CRVS
Corvus Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.23B
5Y Perf.+322.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CRVS vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
CRVS vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CRVS | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.23B | $1712.35T |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-44M | $-168M |
| Total Debt | $937K | $22M |
| Cash & Equiv. | $5M | $194M |
CRVS vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CRVS
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Corvus Pharmaceutic… (CRVS) | 100 | 422.9 | +322.9% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CRVS vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CRVS leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DBV Technologies S.A. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
CRVS
Corvus Pharmaceuticals, Inc.
The Growth Play
CRVS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 48.0%
- 17.1% 10Y total return vs DBVT's -87.0%
- Lower volatility, beta 1.63, Low D/E 1.5%, current ratio 6.21x
Best for: growth exposure and long-term compounding
DBVT
DBV Technologies S.A.
The Income Pick
DBVT is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 0 yrs, beta 1.26
- Beta 1.26, current ratio 3.67x
- Beta 1.26 vs CRVS's 1.63
Best for: income & stability and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CRVS | -6.6% revenue growth vs DBVT's -100.0% |
| Quality / Margins | CRVS | 3.5% margin vs DBVT's 0.3% |
| Stability / Safety | DBVT | Beta 1.26 vs CRVS's 1.63 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CRVS | +355.9% vs DBVT's +110.4% |
| Efficiency (ROA) | CRVS | -35.7% ROA vs DBVT's -89.0% |
CRVS vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCRVSLAGGINGDBVT
DBVTDBV Technologies S.A.
2leads
CRVSCorvus Pharmaceutical…
2leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CRVS6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
CRVS6/6
Risk & VolatilityBeta, volatility, and downside exposure
DBVT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CRVS and DBVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | CRVSCorvus Pharmaceut… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$48M | -$112M |
| Net IncomeAfter-tax profit | -$44M | -$168M |
| Free Cash FlowCash after capex | -$35M | -$151M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -15.4% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — CRVS and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | CRVSCorvus Pharmaceut… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $1.2B | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $1.2B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -27.53x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 19.01x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — CRVS and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CRVS leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
CRVS delivers a -38.9% return on equity — every $100 of shareholder capital generates $-39 in annual profit, vs $-130 for DBVT. CRVS carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs CRVS's 3/9, reflecting mixed financial health.
| Metric | CRVSCorvus Pharmaceut… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -38.9% | -130.2% |
| ROA (TTM)Return on assets | -35.7% | -89.0% |
| ROICReturn on invested capital | -78.1% | — |
| ROCEReturn on capital employed | -90.2% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.02x | 0.13x |
| Net DebtTotal debt minus cash | -$4M | -$172M |
| Cash & Equiv.Liquid assets | $5M | $194M |
| Total DebtShort + long-term debt | $937,000 | $22M |
| Interest CoverageEBIT ÷ Interest expense | -18.29x | -189.82x |
CRVS leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
CRVS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CRVS five years ago would be worth $50,137 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, CRVS leads with a +355.9% total return vs DBVT's +110.4%. The 3-year compound annual growth rate (CAGR) favors CRVS at 123.9% vs DBVT's 6.2% — a key indicator of consistent wealth creation.
| Metric | CRVSCorvus Pharmaceut… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +99.3% | +4.9% |
| 1-Year ReturnPast 12 months | +355.9% | +110.4% |
| 3-Year ReturnCumulative with dividends | +1022.3% | +19.7% |
| 5-Year ReturnCumulative with dividends | +401.4% | -69.1% |
| 10-Year ReturnCumulative with dividends | +17.1% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +123.9% | +6.2% |
CRVS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than CRVS's 1.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs CRVS's 54.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CRVSCorvus Pharmaceut… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.63x | 1.26x |
| 52-Week HighHighest price in past year | $26.95 | $26.18 |
| 52-Week LowLowest price in past year | $3.17 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +54.1% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 49.2 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 252K |
DBVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CRVS as "Buy" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 127.3% for CRVS (target: $33).
| Metric | CRVSCorvus Pharmaceut… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $33.17 | $46.33 |
| # AnalystsCovering analysts | 13 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DBVT leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). CRVS leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallCorvus Pharmaceuticals, Inc. (CRVS)Leads 2 of 6 categories
Loading custom metrics...
CRVS vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CRVS or DBVT a better buy right now?
Analysts rate Corvus Pharmaceuticals, Inc.
(CRVS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CRVS or DBVT?
Over the past 5 years, Corvus Pharmaceuticals, Inc.
(CRVS) delivered a total return of +401. 4%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: CRVS returned +17. 1% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CRVS or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Corvus Pharmaceuticals, Inc. 's 1. 63β — meaning CRVS is approximately 30% more volatile than DBVT relative to the S&P 500. On balance sheet safety, Corvus Pharmaceuticals, Inc. (CRVS) carries a lower debt/equity ratio of 2% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — CRVS or DBVT?
On earnings-per-share growth, the picture is similar: Corvus Pharmaceuticals, Inc.
grew EPS 48. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CRVS or DBVT?
Corvus Pharmaceuticals, Inc.
(CRVS) is the more profitable company, earning 0. 0% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRVS leads at 0. 0% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — CRVS leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CRVS or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CRVS or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Corvus Pharmaceuticals, Inc. (CRVS) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -87. 0%, CRVS: +17. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CRVS and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.